Claims

1. A peptide consisting of:
   a fragment of 16, 17, 18, 19, 20, 21, 22, 23 or 24 consecutive amino acid residues of the DAXX protein of SEQ ID NO:1, wherein said fragment comprises the amino acid sequence set forth in SEQ ID NO: 5, ~~or~~ and
   ~~a fragment of 9, 10, 11, 12, 13, 14, 15, 16 or 17 consecutive amino acid residues of the FADD protein of SEQ ID NO: 8, wherein said fragment comprises the amino acid sequence set forth in SEQ ID NO: 12,~~
   wherein said peptide is capable of inhibiting cell apoptosis.

2. The peptide according to claim 1, wherein said peptide is a DAXX protein fragment and consists of the amino acid sequence set forth in SEQ ID NO: 5 or in any one of SEQ ID NOs: 17-44.

~~3. The peptide according to claim 1, wherein said peptide is a FADD protein fragment and consists of the amino acid sequence set forth in SEQ ID NO: 12 or SEQ ID NO:9 or in any one of SEQ ID NOs: 45-57.~~

43. A peptidomimetic of a peptide according to ~~any one of~~ claims ~~1-3~~ or claim 2.

~~54~~. A conjugate comprising a peptide according to ~~any one of~~ claims ~~1-3~~ or claim 2 or a peptidomimetic ~~thereof~~according to claim 3, wherein said peptide or peptidomimetic is linked to a Cell Penetrating Peptide.

~~65~~. The conjugate according to claim ~~54~~, wherein said peptide or said peptidomimetic is linked to the Cell Penetrating Peptide through a linker.

~~76~~. The conjugate according to claim ~~54~~ or claim ~~65~~, wherein said Cell Penetrating Peptide is selected from the group consisting of Tat, RXR, Bpep and Pip2b.

7. The conjugate according to claim 6, wherein Tat has the sequence set forth in SEQ ID NO:13, RXR has the sequence set forth in SEQ ID NO: 12, Bpep has the sequence set forth in SEQ ID NO: 14 and Pip2b has the sequence set forth in SEQ ID NO: 23.

8. The conjugate according to claim 7, wherein said conjugate consists of the amino acid sequence set forth in SEQ ID NO: 58~~, SEQ ID NO: 59, SEQ ID NO: 60 or SEQ IQ NO: 61~~.

~~9. A pharmaceutical composition comprising an effective amount of at least one peptide according to any one of claims 1-3, or a peptidomimetic thereof~~

9. A pharmaceutical composition comprising an effective amount of at least one peptide according to claim 1 or claim 2, or of at least one peptidomimetic according to claim 3, or of at least one~~a~~ conjugate ~~thereof~~according to any one of claims 4-8, and at least one pharmaceutically acceptable carrier or excipient.

10. The pharmaceutical composition of claim 9 further comprising at least one additional biologically active agent.

11. The pharmaceutical composition according to claim 10, wherein said at least one additional biologically active agent is selected from the group consisting of cyclosporine A, BH4, and combinations thereof.

12. The peptide according to ~~any one of~~ claims 1~~-3~~ or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate ~~thereof~~ according to any one of claims 4-8 or a pharmaceutical composition ~~thereof~~according to any one of claims 9-11, for use in a method of treatment of the human or animal body.

13. The peptide according to ~~any one of~~ claims 1~~-3~~ or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate ~~thereof~~ according to any one of claims 4-8 or a pharmaceutical composition ~~thereof~~according to any one of claims 9-11, for use in a method for inhibiting cell apoptosis in the human or animal body.

14. The peptide according to ~~any one of~~ claims 1~~-3~~ or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate ~~thereof~~ according to any one of claims 4-8 or a pharmaceutical composition ~~thereof~~according to any one of claims 9-11, for use in a method for the treatment of acute myocardial infarction (AMI), cerebral infarction, organ transplantations, cardiac interventions (extra-corporally circulation and temporary vessel occlusion), or acute circulation perturbations (state of shock), in the human or animal body.

15. The peptide according to ~~any one of~~ claims 1~~-3~~ or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate ~~thereof~~ according to any one of claims 4-8 or a pharmaceutical composition ~~thereof~~according to any one of claims 9-11, for use in a method for treatment of ischemia, in particular cardiac ischemia, kidney ischemia, ischemic colitis, mesenteric ischemia, brain ischemia, limb ischemia or skin ischemia, in the human or animal body.

16. The peptide according to ~~any one of~~ claims 1-~~3~~or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate ~~thereof~~ according to any one of claims 4-8 or a pharmaceutical composition ~~thereof~~according to any one of claims 9-11, for use in a method for treatment of reperfusion injury in the human or animal body.

17. The peptide, the derivative ~~thereof~~, the conjugate ~~thereof~~ or the pharmaceutical composition ~~thereof~~ for the use according to any one of claims 12-16, wherein ~~said method also comprises the step of administering~~ cyclosporine A and/or BH4 is also to be administered to said human or animal body.

18. Use of a peptide according to ~~any one of~~ claims ~~1-3~~ or claim 2, or a peptidomimetic ~~thereof~~according to claim 3, or a conjugate according to any one of claims 4-8, for the manufacture of a medicine for the treatment of a disease or condition associated with apoptosis.

19. Use according to claim 18, wherein the medicine further comprises at least one additional biologically active agent selected from the group consisting of cyclosporine A, BH4, and combinations thereof.

20. Use according to claim 18 or claim 19, wherein said disease or condition associated with apoptosis is selected from the group consisting of acute myocardial infarction (AMI), cerebral infarction, organ transplantations, cardiac interventions, acute circulation perturbations, reperfusion injury, and ischemia.